DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc.

Barclays analyst Matt Miksic maintained a Sell rating on Dexcom on May 15 and set a price target of $64.00. The company’s shares closed last Friday...

Barclays Sticks to Its Sell Rating for Dexcom (DXCM)

Traders seeking the hottest stock market stories for Friday will find them in our daily wrap-up.


Morning News Wrap-Up, 5/15/26: Today’s Biggest Stock Market Stories!

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immuneering (IMRX), Galectin Therapeutics (GALT) and...

Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)

Dexcom ($DXCM) stock jumped about 8% on Friday, at the time of writing, as activist investor Elliott Investment Management took a stake in the make...

Why Is Dexcom Stock (DXCM) Soaring Today?

RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Dexcom today and set a price target of $85.00. According to TipRanks, Singh Chad...

RBC Capital Keeps Their Buy Rating on Dexcom (DXCM)

BTIG analyst Marie Thibault reiterated a Buy rating on Dexcom today and set a price target of $80.00. Thibault covers the Healthcare sector, focusi...

BTIG Keeps Their Buy Rating on Dexcom (DXCM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM) and Bristol-Myers Squibb (BMY) with bu...

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Bristol-Myers Squibb (BMY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB), RegenXBio (RGNX) and Dexcom (DXCM) wi...

Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), RegenXBio (RGNX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM) and Tonix Pharma (TNXP) with bullish s...

Analysts’ Top Healthcare Picks: Dexcom (DXCM), Tonix Pharma (TNXP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG ...

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom. The company’s shares closed yesterday at $5...

RBC Capital Remains a Buy on Dexcom (DXCM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Dexcom (DXCM) and Merit Medical Syst...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Dexcom (DXCM) and Merit Medical Systems (MMSI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM). Illumina (ILMN...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM)

In a report released today, from Jefferies reiterated a Buy rating on Dexcom, with a price target of $112.00. In addition to Jefferies, Dexcom also...

Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)

In a report released yesterday, David Roman from Goldman Sachs maintained a Buy rating on Dexcom, with a price target of $80.00. The company’s shar...

Goldman Sachs Sticks to Their Buy Rating for Dexcom (DXCM)

Stifel Nicolaus analyst reiterated a Buy rating on Dexcom today and set a price target of $85.00. In addition to Stifel Nicolaus, Dexcom also recei...

Dexcom (DXCM) Gets a Buy from Stifel Nicolaus

In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on Dexcom, with a price target of $59.00. According to TipRa...

Dexcom (DXCM) Gets a Buy from William Blair

BTIG analyst Marie Thibault maintained a Buy rating on Dexcom yesterday and set a price target of $80.00. The company’s shares closed yesterday at ...

In a report released today, Matt Miksic from Barclays maintained a Sell rating on Dexcom, with a price target of $67.00. According to TipRanks, Mik...

Barclays Keeps Their Sell Rating on Dexcom (DXCM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM) and Sagimet Biosciences, Inc. Class A ...

Current Quarter	$0.6	Next Quarter	$0.66
Current Year	$2.57	Next Year	$3.02
QoQ Growth	+10.0%	YoY Growth	+17.5%
3Y EPS CAGR	+34.5%	Target Price	$81.17
Consensus	Buy	Upside	+12.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DXCM	$72.09	-0.01%	4.28M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DXCM	$72.09	-0.0%	4.28M
3
4
5
6

DXCM

DXCM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get DexCom Inc. Data in Excel

Get DexCom Inc. Data in Excel